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1. Though Duchenne (DMD) and Becker muscular dystrophy (BMD) are associated with 
significant burden, interventions to improve mothers’ psychological adaptation should focus 
on fostering resilience and enhancing benefit finding (this thesis). 
2. Among DMD worries spanning medical and psychosocial domains, parents prioritized child’s 
symptom progression and access to medical care (this thesis). 
3. Parents indicated willingness to accept treatment-related risk for a serious or fatal outcome 
when balanced by slowing progression, even absent lifespan improvement (this thesis).  
4. Parents who consented children to clinical trials described strong decision making pressures 
attributed to the progressive, fatal nature of DMD (this thesis). 
5. Though anticipated benefit to the child was a strong clinical trial motivator, most parents did 
not display true therapeutic misconception (i.e., misunderstanding the intent of clinical trials) 
(this thesis).  
6. Community engagement in research is essential to proposing and answering questions of 
highest relevance, especially when faced with numerous, compelling unmet needs (this 
thesis). 
7. Clinical researchers should engage their disease communities to understand 
patient/caregiver lived experiences, extending beyond what is seen in clinic. 
8. Clinical researchers should appreciate the importance of assessing positive disease 
appraisals and outcomes.  
9. Public health and regulatory policy making should integrate priorities and preferences of 
patients/caregivers. 
10. Severe progressive disorders, where doing nothing is equated with doing harm, requires 
increased regulatory flexibility in research design and implementation.  
11. Researchers exploring clinical trial decision making should advance models integrating and 
differentiating cognitive and emotional influences. 
12. “Decision makers…will make better decisions when they trust their critics to be sophisticated 
and fair, and when they expect their decision to be judged by how it was made, not only by 
how it turned out.” (Kahneman D. Thinking, Fast and Slow, p. 418. New York: Farrar, Straus 
and Giroux, 2011.) 
